ClinicalTrials.gg
RecruitingNCT07136168HOMEUpdated Oct 7, 2025

Healthy Older Adults Through Movement and Engagement

An interventional study of Health dialogue in Frailty, Ageing Well and Prevention Intervention, sponsored by Linkoeping University. Recruiting at 1 site in Sweden. Open to participants aged 67 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-07.

Sponsored by Linkoeping University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,952
Allocation
Randomized
Ages
67 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Frailty with a site in Sweden — 11 open to participants now, 13 under way, none of them phase 3. Frailty · Sweden.

Planned enrollment
2nd of 14
2,952 · median 216
Started
2025
with 3 others
No phase
14 of 32
7 open now
Primary completion
2027-03
later than 6 of 12 live
Registered
31st of 32
by date
Lead sponsor
5 of 32
Linkoeping University

Among the 32 studies in Frailty with a site in Sweden, this one is the 2nd largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2025, is one of 14 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 31st registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

11 of the 32 studies in Frailty with a site in Sweden are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 67 Years to 84 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Frailty with a site in Sweden, or all of them as a file.
02

Study summary

The HOME Project evaluates the effects of structured health dialogues with individuals aged 67-84 years in the municipality of Borgholm, Sweden. A combination of registry data and survey responses will be used to monitor quality of life, morbidity, healthcare needs, and lifestyle factors over a six-year period. Outcomes will be compared between randomized groups within Borgholm municipality and a matched control group from seven other municipalities in Region Kalmar.

The project also includes an analysis of cost-effectiveness and the reach of the intervention. A qualitative interview study will explore participants' perceptions of their health, their motivations for health improvement, and their experiences of how the health dialogues may influence these aspects.

In a substudy, machine learning models will be developed to predict functional decline and high healthcare needs among older adults. These models will be validated against established risk assessment tools such as the Adjusted Clinical Groups (ACG) system and the Charlson Comorbidity Index. Digital motion analysis using Skeleton Avatar Technology will be employed both independently and in combination with other variables to support model development.

Read the detailed description

BACKGROUND: The world faces a demographic shift with an aging population and increasing numbers of older adults experiencing frailty and complex care needs. Effective preventive strategies are requested from many stakeholders . Health dialogues have been introduced in several Swedish regions to promote healthier aging, yet evidence for their effectiveness and cost-efficiency remains limited. While systematic reviews have not confirmed significant effects on morbidity or mortality, some cohort studies suggest benefits in cardiovascular outcomes and a few primary preventive interventions have been directed at older individuals. The results are disputed, and several authors argue that health dialogues and health checks tend to reach individuals with lower cardiovascular risk rather than those at highest risk [4]. There is a lack of studies linking the outcomes of health dialogues to different risk levels.

One strategy to identify individuals in the population at highest risk of morbidity is to use risk assessment instruments. In primary care populations, Adjusted Clinical Groups (ACG) and Charlson Comorbidity Index (CCI) are the most studied. In recent years, several predictive instruments/models using existing health and medical data have been developed to identify older individuals at risk of future functional decline and morbidity. However, the relatively moderate precision of these instruments limits their clinical usefulness. Digital motion analysis using the SAT (Skeleton Avatar Technology) technique has shown potential in assessing physical activity levels, mobility, and balance in older individuals. Still, data from broader populations of older individuals with a wide range of diseases and functional levels are lacking, and the method has not been tested for its predictive ability regarding functional decline and extensive care needs.

Among older individuals, the wide variation in health and functional levels creates a greater need for individualized advice and interventions. Holistic interventions targeting frail older individuals are well-studied, and there is some evidence of positive effects, although results are also conflicting. International recommendations point to a multifactorial causal relationship behind frailty/functional decline, and there is consensus that increased physical activity and reduced malnutrition can counteract these issues, and that an active lifestyle is associated with a reduced risk of frailty.

A current question is which health outcomes are most important for the older population. Studies show that many older individuals value good quality of life and high independence more than maximum lifespan. As a complement to traditional measurements of health-related quality of life using EQ-5D, which focuses on symptoms and function, it is proposed to measure "Capability": the ability to perform activities that are meaningful and important to the individual . ICECAP-O is a quality-of-life instrument that has also been used for health economic evaluations [9].

AIM:

We will evaluate the short - and long term effects of preventive health dialogues for older individuals. The project also aims to evaluate and further develop models to predict the risk of future illness. We will also examine which residents choose to participate and how participation affects both self-rated health and quality of life, as well as health and social care needs. This is important from an equity perspective: can health dialogues help reduce health disparities, or is there a risk that they reinforce existing inequalities in health between groups? For the same reason, we are conducting a cost-effectiveness analysis of health dialogues in an older population, examining the balance between cost and benefit.

The qualitative part of the project aims to increase understanding of what happens in the communication during health dialogues and what older individuals themselves perceive as influencing their motivation to take personal responsibility for their health.

Research questions:

  1. How does quality of life develop in the intervention group offered health dialogues compared to a) a randomized control group in the same municipality and b) a matched control group in a neighboring county?
  2. How do function, activity, and use of health and social care services develop in these groups?
  3. Is the health dialogue intervention cost-effective?
  4. Are there differences in risk levels and health outcomes between participants in health dialogues and those who choose not to participate?
  5. Is the effect of health dialogues influenced by the participant's risk level for morbidity and adverse health outcomes?
  6. Can digital motion analysis be used to predict the risk of future morbidity and functional decline?
  7. What do participants describe as influencing and motivating them to improve their health, and how do they reason about the priorities they make regarding their health? The primary outcome measure is quality of life, assessed using two complementary methods: EQ-5D and ICECAP-O. We include a broad age range of participants from early retirement age and upwards to gain more knowledge about which groups have the greatest need for and benefit from health dialogues.

    ________________________________________

    Hypotheses:

    • Health dialogues should be targeted at specific risk groups within the older population to be cost-effective.
    • Digital motion analysis using Skeleton Avatar Technology (SAT) can be used alone or in combination with other variables to identify older individuals at high risk of developing functional decline and extensive care needs.

    STUDY DESIGN This is a mixed-methods study combining quantitative and qualitative approaches.The quantitative component includes a controlled intervention study with three groups: intervention, randomized control, and matched control. The qualitative component explores participants' experiences and perceptions through interviews and thematic analysis.

    DATA COLLECTION Outcomes 1,2,11 and 12 will be collected by a postal/web-based questionnaire. All other outcomes will be collected from healthcare registries.

    ANALYSIS

    Effects of Health Dialogues:

    The following comparative analyses will be conducted:

    A: Differences between the intervention arm and the passive control arm (overall and stratified by risk level).

    B: Differences between the two randomized arms and the matched controls (overall and stratified by risk level).

    C: Differences between participants and non-participants within the intervention arm (overall and stratified by risk level).

    Differences in primary outcomes between intervention and control groups will be estimated using 95% confidence intervals. Appropriate statistical methods will be applied based on the type of outcome measure. Subgroup estimates will be calculated similarly, and relevant statistical tests for heterogeneity will be used. Risk stratification will be based on Adjusted Clinical Groups (ACG), Charlson Comorbidity Index (CCI), frailty status, and a predictive model for hospital admissions.

    The aim of these analyses is to obtain unbiased estimates of statistically significant differences in outcomes between groups. Given the randomized design, statistically significant differences will be interpreted as effects of the intervention. Analyses will follow the intention-to-treat (ITT) principle, which maintains group assignment throughout the study and is appropriate for this design.

    Cost-Effectiveness Analysis:

    The cost-effectiveness evaluation will estimate the total costs of the intervention using established health economic methods. The analysis will adopt a societal perspective. Costs will be compared to selected outcome measures and benchmarked against alternative resource use scenarios, such as no health dialogue or other similar interventions.

    Development of Risk Prediction Models:

    A combination of variables from electronic health records (diagnoses, healthcare contacts), surveys (self-rated health, symptoms, lifestyle factors), and digital motion analysis (SAT) will be collected. Machine learning models will be trained on these data to predict functional decline (ADL limitations and care needs) and morbidity (hospitalizations, healthcare visits, mortality). Techniques such as logistic regression, random forest, and neural networks will be used to optimize prediction accuracy. Model performance will be evaluated using AUC/ROC (Receiver Operating Characteristic Curve) and MAE (Mean Absolute Error).

    Motivational Factors in Health Dialogues:

    The qualitative sub-study aims to explore whether and how health dialogues influence motivation for adopting health-promoting behaviors. Interviews will focus on changes in participants' views on personal responsibility for health, lifestyle choices, and behavioral change. Data will be analyzed using qualitative content analysis, without predefined categories or themes.

03

Conditions studied

  • Frailty
  • Ageing Well
  • Prevention Intervention
  • Health Related Quality of Life

Browse trials for

Keywords

  • health dialogue
  • frailty
  • cost-effectiveness
  • ageing well
  • primary care
  • health related quality of life
04

Who can participate

Ages eligible
67 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Living in Borgholm municipality or in one of 7 matched Demographical Statistical Area in Kalmar county
  • Age between 67-84 years

Exclusion criteria

Exclusion Criteria:

  • Living in a nursing home
  • Not speaking or understanding swedish language
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,952 participants (estimated)

Study arms

  • Experimental
    Health dialogue

    Participants will be invited to a health dialogue at primary health care center and to answer a questionnaire covering different aspects of health. Data from medical registers will be collected.

    Behavioral: Health dialogue

  • No intervention
    Passive control

    Participant will be invited to answer a questionnaire covering different aspects of health. Data from medical registers will be collected.

Interventions

  • BehavioralHealth dialogue

    1. Pre-visit 20 minutes including timed-up and go (TUG) walking test, length, weight, blood pressure, and blood tests ( HbA1C, PEth) 2. Structured health dialogue by a dedicated nurse practitioner for about 60 minutes covering living conditions, activity, everyday function, lifestyle habits and formation of a plan for improved health and referral to physician, physiotherapist or other primary care worker when appropriate 3. Follow-up call at 3 months with the nurse practitioner for evaluation and adjustment of the plan

06

What researchers measure

Primary outcomes

  1. Change in health-related quality of life

    EQ5D-5L (Euroqol 5 dimensions 5 levels) collected via postal questionnaire

    Time frame: Baseline, at 16 months and 6 years from start of intervention

  2. Change in quality of life

    Quality of life measured by ICECAP-0 ( ICEpop CAPability measure for older people)

    Time frame: Baseline, at 16 months and at 6 years from study start

Secondary outcomes

  1. Hospital care days

    the total number of days that a participant is admitted to hospital

    Time frame: 16 months, 3 years and 6 years

  2. Hospital care episodes

    The number of events a patient is admitted to hospital regardless of length of stay

    Time frame: 16 months, 3 years and 6 years

  3. Healthcare visits

    The number of out-patient visits to physician or other healthcare profession in primary or secondary care

    Time frame: 16 months, 3 years and 6 years from start of intervention

  4. Social care use

    Number and type of services delivered from the municipality

    Time frame: 16 months and 6 years from the start of the intervention

  5. Mortality

    All-cause mortality

    Time frame: 16 months, 3 years and 6 years from start of intervention

  6. Healthcare cost

    Total healthcare cost including primary, secondary out-patient care, community care and hospital care

    Time frame: 16 months, 3 years and 6 years from start of intervention

  7. Cost-effectiveness

    Incremental cost-effectiveness ratio (ICER) calculated by QALYs and YSC (Years of sufficient capability)

    Time frame: 16 months and 6 years from start of intervention

  8. Change in ADL (Activities of daily living)

    Activities of daily living measured by the ADL-staircase. 9 activities ( 5 Personal and 4 instrumental ADLs.

    Time frame: at baseline, 16 months and 6 years from start of intervention

  9. Frailty

    Self-reported frailty criteria derived from Frieds frailty phenotype. Five criteria, reporting of 2 crietria indicates pre-frailty and 3 criteria or more indicates frailty,

    Time frame: Baseline, at 16 months and 6 years from start of intervention

  10. Time to nursing home admission

    Number of days/months that a participant stays in independent living from study start to nursing home admission

    Time frame: 16 months and 6 years from start of intervention

  11. Medication

    Number and type of prescribed drugs

    Time frame: 16 months and 6 years from start of intervention

  12. Maintenance of own housing

    Number of days living in independent housing from study start to admission to nursing home

    Time frame: At 16 months, at 3 years and 6 years from start of intervention

07

Study locations

1 of 1 sites recruiting
  • Hälsocentralen i Borgholm
    Borgholm, County of Kalmar SE - 58216, Sweden
    Recruiting
08

References and documents

Publications

  • Proud L, McLoughlin C, Kinghorn P. ICECAP-O, the current state of play: a systematic review of studies reporting the psychometric properties and use of the instrument over the decade since its publication. Qual Life Res. 2019 Jun;28(6):1429-1439. doi: 10.1007/s11136-019-02114-y. Epub 2019 Jan 21. PubMed 30666550 ↗
  • van Leeuwen KM, van Loon MS, van Nes FA, Bosmans JE, de Vet HCW, Ket JCF, Widdershoven GAM, Ostelo RWJG. What does quality of life mean to older adults? A thematic synthesis. PLoS One. 2019 Mar 8;14(3):e0213263. doi: 10.1371/journal.pone.0213263. eCollection 2019. PubMed 30849098 ↗
  • Apostolo J, Cooke R, Bobrowicz-Campos E, Santana S, Marcucci M, Cano A, Vollenbroek-Hutten M, Germini F, D'Avanzo B, Gwyther H, Holland C. Effectiveness of interventions to prevent pre-frailty and frailty progression in older adults: a systematic review. JBI Database System Rev Implement Rep. 2018 Jan;16(1):140-232. doi: 10.11124/JBISRIR-2017-003382. PubMed 29324562 ↗
  • Lincke A, Fagerstrom C, Ekstedt M, Lowe W, Backaberg S. A comparative study of the 2D- and 3D-based skeleton avatar technology for assessing physical activity and functioning among healthy older adults. Health Informatics J. 2023 Oct-Dec;29(4):14604582231214589. doi: 10.1177/14604582231214589. PubMed 37924210 ↗
  • Klunder JH, Panneman SL, Wallace E, de Vries R, Joling KJ, Maarsingh OR, van Hout HPJ. Prediction models for the prediction of unplanned hospital admissions in community-dwelling older adults: A systematic review. PLoS One. 2022 Sep 23;17(9):e0275116. doi: 10.1371/journal.pone.0275116. eCollection 2022. PubMed 36149932 ↗
  • Girwar SM, Jabroer R, Fiocco M, Sutch SP, Numans ME, Bruijnzeels MA. A systematic review of risk stratification tools internationally used in primary care settings. Health Sci Rep. 2021 Jul 23;4(3):e329. doi: 10.1002/hsr2.329. eCollection 2021 Sep. PubMed 34322601 ↗
  • Bender AM, Jorgensen T, Pisinger C. Is self-selection the main driver of positive interpretations of general health checks? The Inter99 randomized trial. Prev Med. 2015 Dec;81:42-8. doi: 10.1016/j.ypmed.2015.07.004. Epub 2015 Jul 17. PubMed 26190370 ↗
  • Nordstrom A, Bergman J, Bjork S, Carlberg B, Johansson J, Hult A, Nordstrom P. A multiple risk factor program is associated with decreased risk of cardiovascular disease in 70-year-olds: A cohort study from Sweden. PLoS Med. 2020 Jun 11;17(6):e1003135. doi: 10.1371/journal.pmed.1003135. eCollection 2020 Jun. PubMed 32525878 ↗
  • Krogsboll LT, Jorgensen KJ, Gotzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev. 2019 Jan 31;1(1):CD009009. doi: 10.1002/14651858.CD009009.pub3. PubMed 30699470 ↗
  • Salomon JA, Wang H, Freeman MK, Vos T, Flaxman AD, Lopez AD, Murray CJ. Healthy life expectancy for 187 countries, 1990-2010: a systematic analysis for the Global Burden Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2144-62. doi: 10.1016/S0140-6736(12)61690-0. PubMed 23245606 ↗

Individual participant data

Plan to share: Undecided — Data may be made available upon request when the study is completed following the laws for sharing patient data

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Mar 2027, 19 months after the start.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 19 months is below that.

Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 22, 2025
StartActual
Aug 25, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Dec 31, 2031
Last update
Oct 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07136168
Collaborators
Linnaeus University, Department of Clinical Sciences, Malmö. Faculty of Medicine, Lund University., Göteborg University
Responsible party
Magnus Nord (MD, PhD; Adjunct senior lecturer, Linkoeping University) — Principal investigator
First posted
Aug 22, 2025
Start date
Aug 25, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Oct 7, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion